Abstract:• NLRP3 inflammasome is activated with increased NLRP3 acetylation in Tauopathy transgenic mice and AD patients. • Tau promotes NLRP3 acetylation and inflammasome activation dependent on K18 acetyltransferase activity domain. • Tau directly acetylates NLRP3 at K21, K22 and K24 site at its PYD domain and thereby induce inflammasome activation in vitro. • Tau overexpression in mouse hippocampal CA1 neurons induces cognitive impairment, Tau transmission to microglia and microgliosis with NLRP3 acetylation and inflammasome activation. • Competitive binding of a designed TNB peptide to block the interaction of Tau with NLRP3 inhibits the NLRP3 acetylation and downstream inflammasome activation in microglia, thereby alleviating cognitive impairment in mice. Background Alzheimer's disease (AD) and related Tauopathies are characterised by the pathologically hyperphosphorylated and aggregated microtubule‐associated protein Tau, which is accompanied by neuroinflammation mediated by activated microglia. However, the role of Tau pathology in microglia activation or their causal relationship remains largely elusive. Methods The levels of nucleotide‐binding oligomerisation domain (NOD)‐like receptor pyrin domain containing 3 (NLRP3) acetylation and inflammasome activation in multiple cell models with Tau proteins treatment, transgenic mice with Tauopathy, and AD patients were measured by Western blotting and enzyme‐linked immunosorbent assay. In addition, the acetyltransferase activity of Tau and NLRP3 acetylation sites were confirmed using the test‐tube acetylation assay, co‐immunoprecipitation, immunofluorescence (IF) staining, mass spectrometry and molecular docking. The Tau‐overexpressing mouse model was established by overexpression of human Tau proteins in mouse hippocampal CA1 neurons through the adeno‐associated virus injection. The cognitive functions of Tau‐overexpressing mice were assessed in various behavioural tests, and microglia activation was analysed by Iba‐1 IF staining and [18F]‐DPA‐714 positron emission tomography/computed tomography imaging. A peptide that blocks the interaction between Tau and NLRP3 was synthesised to determine the in vitro and in vivo effects of Tau–NLRP3 interaction blockade on NLRP3 acetylation, inflammasome activation, microglia activation and cognitive function. Results Excessively elevated NLRP3 acetylation and inflammasome activation were observed in 3xTg‐AD mice, microtubule‐associated protein Tau P301S (PS19) mice and AD patients. It was further confirmed that mimics of 'early' phosphorylated‐Tau proteins which increase at the initial stage of diseases with Tauopathy, including TauT181E, TauS199E, TauT217E and TauS262E, significantly promoted Tau–K18 domain acetyltransferase activity‐dependent NLRP3 acetylation and inflammasome activation in HEK293T and BV‐2 microglial cells. In addition, Tau protein could directly acetylate NLRP3 at the K21, K22 and K24 sites at its PYD domain and thereby induce inflammasome activation in vitro. Overexpression of human Tau proteins in mouse hippocampal CA1 neurons resulted in impaired cognitive function, Tau transmission to microglia and microgliosis with NLRP3 acetylation and inflammasome activation. As a targeted intervention, competitive binding of a designed Tau–NLRP3‐binding blocking (TNB) peptide to block the interaction of Tau protein with NLRP3 inhibited the NLRP3 acetylation and downstream inflammasome activation in microglia, thereby alleviating microglia activation and cognitive impairment in mice. Conclusions In conclusion, our findings provide evidence for a novel role of Tau in the regulation of microglia activation through acetylating NLRP3, which has potential implications for early intervention and personalised treatment of AD and related Tauopathies.

Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex

Astrocytic accumulation of tau fibrils isolated from Alzheimer's disease brains induces inflammation, cell-to-cell propagation and neuronal impairment

Properties of Alzheimer’s disease brain-derived tau aggregates define tau processing by human astrocytes

Fate and propagation of endogenously formed Tau aggregates in neuronal cells

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

G-protein coupled receptors regulates Tauopathy in neurodegeneration

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent inflammatory responses

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Astrocytic tau inclusions lead to microglial abnormalities, but leave neuronal networks intact

Phagocytosis of full-length Tau oligomers by Actin-remodeling of activated microglia

Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)

Activity-Dependent Tau Protein Translocation to Excitatory Synapse Is Disrupted by Exposure to Amyloid-Beta Oligomers

Overexpression of pathogenic tau in astrocytes causes a reduction in AQP4 and GLT1, an immunosuppressed phenotype and unique transcriptional responses to repetitive mild TBI without appreciable changes in tauopathy

Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

Aβ “Stretching-and-packing” Cross-Seeding Mechanism Can Trigger Tau Protein Aggregation

Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells

Tau internalization: A complex step in tau propagation

Tau induces inflammasome activation and microgliosis through acetylating NLRP3

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy